Chongqing Huiyuan Pharma Acquires Singapore Chinese Medicines And Health
This article was originally published in PharmAsia News
Executive SummaryChongqing Huiyuan Pharma has recently completed the acquisition of Singapore's second-largest pharmaceutical retail chain company - Singapore Chinese Medicines and Health - with RMB 10 million ($1.46 million). Huiyuan will set up a large-scale one-stop TCM supermarket in Singapore that integrates diagnosis services by TCM physicians and sale of health products and Chinese herbal slices. The firm will also establish branches in Southeast Asia to develop TCM clinics, training, exhibition and wholesale businesses. The acquisition is set to boost sales of Chongqing-made Chinese crude medicines and herbal slices in the Singapore market, as well as enhance Chongqing city's TCM product expansion in Southeast Asia. (Click here for more - Chinese Language)
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.